These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Harousseau JL; Attal M Semin Hematol; 1997 Jan; 34(1 Suppl 1):61-6. PubMed ID: 9122747 [TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. Attal M; Harousseau JL; Stoppa AM; Sotto JJ; Fuzibet JG; Rossi JF; Casassus P; Maisonneuve H; Facon T; Ifrah N; Payen C; Bataille R N Engl J Med; 1996 Jul; 335(2):91-7. PubMed ID: 8649495 [TBL] [Abstract][Full Text] [Related]
5. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076 [TBL] [Abstract][Full Text] [Related]
6. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. Fermand JP; Katsahian S; Divine M; Leblond V; Dreyfus F; Macro M; Arnulf B; Royer B; Mariette X; Pertuiset E; Belanger C; Janvier M; Chevret S; Brouet JC; Ravaud P; J Clin Oncol; 2005 Dec; 23(36):9227-33. PubMed ID: 16275936 [TBL] [Abstract][Full Text] [Related]
7. [Autograft and multiple myeloma: experience of the Intergroupe Français du Myélome]. Attal M; Harousseau JL Bull Cancer; 2001 Sep; 88(9):888-92. PubMed ID: 11604362 [TBL] [Abstract][Full Text] [Related]
8. Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma. Galli M; Nicolucci A; Valentini M; Belfiglio M; Delaini F; Crippa C; Barbui AM; Giussani U; Rambaldi A; Barbui T Haematologica; 2005 Dec; 90(12):1643-9. PubMed ID: 16330437 [TBL] [Abstract][Full Text] [Related]
10. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future. Björkstrand B; Gahrton G Semin Hematol; 2007 Oct; 44(4):227-33. PubMed ID: 17961721 [TBL] [Abstract][Full Text] [Related]
11. Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogenic. Gibson J; Ho PJ; Joshua D Transplant Proc; 2004 Oct; 36(8):2501-3. PubMed ID: 15561295 [TBL] [Abstract][Full Text] [Related]
12. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bladé J; Esteve J; Rives S; Martínez C; Rovira M; Urbano-Ispizua A; Marín P; Carreras E; Montserrat E Bone Marrow Transplant; 2000 Oct; 26(8):845-9. PubMed ID: 11081383 [TBL] [Abstract][Full Text] [Related]
13. Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma. Abraham R; Chen C; Tsang R; Simpson D; Murray C; Davidson M; Meharchand J; Sutton DM; Crump RM; Keating A; Stewart AK Bone Marrow Transplant; 1999 Dec; 24(12):1291-7. PubMed ID: 10627637 [TBL] [Abstract][Full Text] [Related]
14. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279 [TBL] [Abstract][Full Text] [Related]
15. Allogeneic bone marrow transplantation for the treatment of multiple myeloma. An overview of published reports. Cavo M; Benni M; Cirio TM; Gozzetti A; Tura S Stem Cells; 1995 Aug; 13 Suppl 2():126-31. PubMed ID: 8520501 [TBL] [Abstract][Full Text] [Related]
16. Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma. Reece DE; Brockington DA; Phillips GL; Barnett MJ; Klingemann HG; Nantel SH; Sutherland HJ; Shepherd JD Bone Marrow Transplant; 2000 Sep; 26(6):621-6. PubMed ID: 11041567 [TBL] [Abstract][Full Text] [Related]
17. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130 [TBL] [Abstract][Full Text] [Related]